Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Delphine Dayde, Ichidai Tanaka, Rekha Jain, Mei Chee Tai, Ayumu Taguchi, Delphine Dayde, Ichidai Tanaka, Rekha Jain, Mei Chee Tai, Ayumu Taguchi

Abstract

The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation (nCRT) followed by radical surgery. Response to nCRT varies among patients and pathological complete response is associated with better outcome. However, there is a lack of effective methods to select rectal cancer patients who would or would not have a benefit from nCRT. The utility of clinicopathological and radiological features are limited due to lack of adequate sensitivity and specificity. Molecular biomarkers have the potential to predict response to nCRT at an early time point, but none have currently reached the clinic. Integration of diverse types of biomarkers including clinicopathological and imaging features, identification of mechanistic link to tumor biology, and rigorous validation using samples which represent disease heterogeneity, will allow to develop a sensitive and cost-effective molecular biomarker panel for precision medicine in rectal cancer. Here, we aim to review the recent advance in tissue- and blood-based molecular biomarker research and illustrate their potential in predicting nCRT response in rectal cancer.

Keywords: biomarker; neoadjuvant chemoradiation; rectal cancer.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210.
    1. Bailey C.E., Hu C.Y., You Y.N., Bednarski B.K., Rodriguez-Bigas M.A., Skibber J.M., Cantor S.B., Chang G.J. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 2015;150:17–22. doi: 10.1001/jamasurg.2014.1756.
    1. Yang Y., Huang X., Sun J., Gao P., Song Y., Chen X., Zhao J., Wang Z. Prognostic value of perineural invasion in colorectal cancer: A meta-analysis. J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract. 2015;19:1113–1122. doi: 10.1007/s11605-015-2761-z.
    1. Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., Martus P., Tschmelitsch J., Hager E., Hess C.F., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004;351:1731–1740. doi: 10.1056/NEJMoa040694.
    1. Sauer R., Liersch T., Merkel S., Fietkau R., Hohenberger W., Hess C., Becker H., Raab H.R., Villanueva M.T., Witzigmann H., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012;30:1926–1933. doi: 10.1200/JCO.2011.40.1836.
    1. Roh M.S., Colangelo L.H., O’Connell M.J., Yothers G., Deutsch M., Allegra C.J., Kahlenberg M.S., Baez-Diaz L., Ursiny C.S., Petrelli N.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009;27:5124–5130. doi: 10.1200/JCO.2009.22.0467.
    1. Bosset J.F., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., Bardet E., Beny A., Ollier J.C., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 2006;355:1114–1123. doi: 10.1056/NEJMoa060829.
    1. Liu G.C., Yan J.P., He Q., An X., Pan Z.Z., Ding P.R. Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis. Gastroenterol. Res. Pract. 2016;2016:1798285. doi: 10.1155/2016/1798285.
    1. Yang Y.J., Cao L., Li Z.W., Zhao L., Wu H.F., Yue D., Yang J.L., Zhou Z.R., Liu S.X. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis. Oncotarget. 2016;7:45513–45524. doi: 10.18632/oncotarget.9995.
    1. Collette L., Bosset J.F., den Dulk M., Nguyen F., Mineur L., Maingon P., Radosevic-Jelic L., Pierart M., Calais G., European Organisation for Research and Treatment of Cancer Radiation Oncology Group Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007;25:4379–4386.
    1. Park I.J., You Y.N., Agarwal A., Skibber J.M., Rodriguez-Bigas M.A., Eng C., Feig B.W., Das P., Krishnan S., Crane C.H., et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012;30:1770–1776. doi: 10.1200/JCO.2011.39.7901.
    1. Silberfein E.J., Kattepogu K.M., Hu C.Y., Skibber J.M., Rodriguez-Bigas M.A., Feig B., Das P., Krishnan S., Crane C., Kopetz S., et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann. Surg. Oncol. 2010;17:2863–2869. doi: 10.1245/s10434-010-1119-8.
    1. Smith K.D., Tan D., Das P., Chang G.J., Kattepogu K., Feig B.W., Skibber J.M., Rodriguez-Bigas M.A. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann. Surg. 2010;251:261–264. doi: 10.1097/SLA.0b013e3181bdfc27.
    1. Ryan J.E., Warrier S.K., Lynch A.C., Heriot A.G. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review. Colorectal Dis. Off. J. Assoc. Coloproctol. Great Br. Irel. 2015;17:849–861. doi: 10.1111/codi.13081.
    1. Fokas E., Liersch T., Fietkau R., Hohenberger W., Beissbarth T., Hess C., Becker H., Ghadimi M., Mrak K., Merkel S., et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO/ARO/AIO-94 trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014;32:1554–1562. doi: 10.1200/JCO.2013.54.3769.
    1. Pozo M.E., Fang S.H. Watch and wait approach to rectal cancer: A review. World J. Gastrointest. Surg. 2015;7:306–312. doi: 10.4240/wjgs.v7.i11.306.
    1. Renehan A.G., Malcomson L., Emsley R., Gollins S., Maw A., Myint A.S., Rooney P.S., Susnerwala S., Blower A., Saunders M.P., et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174–183. doi: 10.1016/S1470-2045(15)00467-2.
    1. Martens M.H., Maas M., Heijnen L.A., Lambregts D.M., Leijtens J.W., Stassen L.P., Breukink S.O., Hoff C., Belgers E.J., Melenhorst J., et al. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer. J. Natl. Cancer Inst. 2016;108 doi: 10.1093/jnci/djw171.
    1. Ferrari L., Fichera A. Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol. Rep. 2015;3:277–288. doi: 10.1093/gastro/gov039.
    1. Bitterman D.S., Resende Salgado L., Moore H.G., Sanfilippo N.J., Gu P., Hatzaras I., Du K.L. Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer. Front. Oncol. 2015;5:286. doi: 10.3389/fonc.2015.00286.
    1. Zeng W.G., Liang J.W., Wang Z., Zhang X.M., Hu J.J., Hou H.R., Zhou H.T., Zhou Z.X. Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Chin. J. Cancer. 2015;34:468–474. doi: 10.1186/s40880-015-0033-7.
    1. Huh J.W., Kim H.R., Kim Y.J. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis. Colon Rectum. 2013;56:698–703. doi: 10.1097/DCR.0b013e3182837e5b.
    1. Qiu H.Z., Wu B., Xiao Y., Lin G.L. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. Colorectal Dis. Off. J. Assoc. Coloproctol. Great Br. Irel. 2011;13:1353–1360. doi: 10.1111/j.1463-1318.2011.02570.x.
    1. McCawley N., Clancy C., O’Neill B.D., Deasy J., McNamara D.A., Burke J.P. Mucinous Rectal Adenocarcinoma Is Associated with a Poor Response to Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis. Dis. Colon Rectum. 2016;59:1200–1208. doi: 10.1097/DCR.0000000000000635.
    1. Bipat S., Glas A.S., Slors F.J., Zwinderman A.H., Bossuyt P.M., Stoker J. Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—A meta-analysis. Radiology. 2004;232:773–783. doi: 10.1148/radiol.2323031368.
    1. Lahaye M.J., Engelen S.M., Nelemans P.J., Beets G.L., van de Velde C.J., van Engelshoven J.M., Beets-Tan R.G. Imaging for predicting the risk factors—The circumferential resection margin and nodal disease--of local recurrence in rectal cancer: A meta-analysis. Semin. Ultrasound CT MR. 2005;26:259–268. doi: 10.1053/j.sult.2005.04.005.
    1. Van der Paardt M.P., Zagers M.B., Beets-Tan R.G., Stoker J., Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: A systematic review and meta-analysis. Radiology. 2013;269:101–112. doi: 10.1148/radiol.13122833.
    1. Memon S., Lynch A.C., Bressel M., Wise A.G., Heriot A.G. Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis. Off. J. Assoc. Coloproctol. Great Br. Irel. 2015;17:748–761. doi: 10.1111/codi.12976.
    1. Sclafani F., Brown G., Cunningham D., Wotherspoon A., Tait D., Peckitt C., Evans J., Yu S., Sena Teixeira Mendes L., Tabernero J., et al. PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO. 2016;27:1557–1565. doi: 10.1093/annonc/mdw215.
    1. Patel U.B., Taylor F., Blomqvist L., George C., Evans H., Tekkis P., Quirke P., Sebag-Montefiore D., Moran B., Heald R., et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29:3753–3760. doi: 10.1200/JCO.2011.34.9068.
    1. Joye I., Deroose C.M., Vandecaveye V., Haustermans K. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2014;113:158–165. doi: 10.1016/j.radonc.2014.11.026.
    1. Li N., Dou L., Zhang Y., Jin J., Wang G., Xiao Q., Li Y., Wang X., Ren H., Fang H., et al. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer. Gastrointest. Endoscopy. 2016;85:669–674. doi: 10.1016/j.gie.2016.06.042.
    1. Ryan J.E., Warrier S.K., Lynch A.C., Ramsay R.G., Phillips W.A., Heriot A.G. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review. Colorectal Dis. 2016;18:234–246. doi: 10.1111/codi.13207.
    1. Trakarnsanga A., Gonen M., Shia J., Nash G.M., Temple L.K., Guillem J.G., Paty P.B., Goodman K.A., Wu A., Gollub M., et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J. Natl. Cancer Inst. 2014;106 doi: 10.1093/jnci/dju248.
    1. Kim S.H., Chang H.J., Kim D.Y., Park J.W., Baek J.Y., Kim S.Y., Park S.C., Oh J.H., Yu A., Nam B.H. What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy? Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2016;48:998–1009. doi: 10.4143/crt.2015.254.
    1. Chen M.B., Wu X.Y., Yu R., Li C., Wang L.Q., Shen W., Lu P.H. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: A meta-analysis in rectal cancer. PLoS ONE. 2012;7:e45388. doi: 10.1371/journal.pone.0045388.
    1. Sakai K., Kazama S., Nagai Y., Murono K., Tanaka T., Ishihara S., Sunami E., Tomida S., Nishio K., Watanabe T. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget. 2014;5:9641–9649. doi: 10.18632/oncotarget.2438.
    1. Luna-Perez P., Segura J., Alvarado I., Labastida S., Santiago-Payan H., Quintero A. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann. Surg. Oncol. 2000;7:727–731. doi: 10.1007/s10434-000-0727-0.
    1. Zauber N.P., Marotta S.P., Berman E., Grann A., Rao M., Komati N., Ribiero K., Bishop D.T. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:472–476. doi: 10.1016/j.ijrobp.2008.08.020.
    1. Gaedcke J., Grade M., Jung K., Schirmer M., Jo P., Obermeyer C., Wolff H.A., Herrmann M.K., Beissbarth T., Becker H., et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2010;94:76–81. doi: 10.1016/j.radonc.2009.10.001.
    1. Bengala C., Bettelli S., Bertolini F., Sartori G., Fontana A., Malavasi N., Depenni R., Zironi S., del Giovane C., Luppi G., et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br. J. Cancer. 2010;103:1019–1024. doi: 10.1038/sj.bjc.6605853.
    1. Davies J.M., Trembath D., Deal A.M., Funkhouser W.K., Calvo B.F., Finnegan T., Weck K.E., Tepper J.E., O’Neil B.H. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiat. Oncol. 2011;6:114. doi: 10.1186/1748-717X-6-114.
    1. Martellucci J., Alemanno G., Castiglione F., Bergamini C., Valeri A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg. 2015;67:47–53. doi: 10.1007/s13304-015-0281-8.
    1. Duldulao M.P., Lee W., Nelson R.A., Li W., Chen Z., Kim J., Garcia-Aguilar J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann. Surg. Oncol. 2013;20:2166–2171. doi: 10.1245/s10434-013-2910-0.
    1. Garcia-Aguilar J., Chen Z., Smith D.D., Li W., Madoff R.D., Cataldo P., Marcet J., Pastor C. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann. Surg. 2011;254:486–492. doi: 10.1097/SLA.0b013e31822b8cfa.
    1. Issa J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer. 2004;4:988–993. doi: 10.1038/nrc1507.
    1. Williamson J.S., Harris D.A., Beynon J., Jenkins G.J. Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer. Clin. Epigenet. 2015;7:70. doi: 10.1186/s13148-015-0111-3.
    1. Gaedcke J., Leha A., Claus R., Weichenhan D., Jung K., Kitz J., Grade M., Wolff H.A., Jo P., Doyen J., et al. Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. Oncotarget. 2014;5:8123–8135. doi: 10.18632/oncotarget.2347.
    1. Watanabe T., Komuro Y., Kiyomatsu T., Kanazawa T., Kazama Y., Tanaka J., Tanaka T., Yamamoto Y., Shirane M., Muto T., et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006;66:3370–3374. doi: 10.1158/0008-5472.CAN-05-3834.
    1. Agostini M., Zangrando A., Pastrello C., D’Angelo E., Romano G., Giovannoni R., Giordan M., Maretto I., Bedin C., Zanon C., et al. A functional biological network centered on XRCC3: A new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol. Ther. 2015;16:1160–1171.
    1. Agostini M., Janssen K.P., Kim I.J., D’Angelo E., Pizzini S., Zangrando A., Zanon C., Pastrello C., Maretto I., Digito M., et al. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget. 2015;6:32561–32574.
    1. Guo Y., Cheng J., Ao L., Li X., Guan Q., Zhang J., Yan H., Cai H., Gao Q., Jiang W., et al. Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers. Sci. Rep. 2016;6:36935. doi: 10.1038/srep36935.
    1. Gim J., Cho Y.B., Hong H.K., Kim H.C., Yun S.H., Wu H.G., Jeong S.Y., Joung J.G., Park T., Park W.Y., et al. Predicting multi-class responses to preoperative chemoradiotherapy in rectal cancer patients. Radiat. Oncol. 2016;11:50. doi: 10.1186/s13014-016-0623-9.
    1. Gantt G.A., Chen Y., Dejulius K., Mace A.G., Barnholtz-Sloan J., Kalady M.F. Gene expression profile is associated with chemoradiation resistance in rectal cancer. Colorectal Dis. Off. J. Assoc. Coloproctol. Great Br. Irel. 2014;16:57–66. doi: 10.1111/codi.12395.
    1. Karagkounis G., Thai L., de Vecchio J., Gantt G.A., Duraes L., Pai R.K., Kalady M.F. NPTX2 is associated with neoadjuvant therapy response in rectal cancer. J. Surg. Res. 2016;202:112–117. doi: 10.1016/j.jss.2015.12.042.
    1. Kim N.K., Hur H. New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer. Yonsei Med. J. 2015;56:1461–1477. doi: 10.3349/ymj.2015.56.6.1461.
    1. Molinari C., Matteucci F., Caroli P., Passardi A. Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. Clin. Colorectal Cancer. 2015;14:227–238. doi: 10.1016/j.clcc.2015.05.014.
    1. Qin C.J., Song X.M., Chen Z.H., Ren X.Q., Xu K.W., Jing H., He Y.L. XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. Oncotarget. 2015;6:32193–32204.
    1. Ho V., Chung L., Revoltar M., Lim S.H., Tut T.G., Abubakar A., Henderson C.J., Chua W., Ng W., Lee M., et al. MRE11 and ATM Expression Levels Predict Rectal Cancer Survival and Their Association with Radiotherapy Response. PLoS ONE. 2016;11:e0167675. doi: 10.1371/journal.pone.0167675.
    1. Yan R., Zhu K., Dang C., Lan K., Wang H., Yuan D., Chen W., Meltzer S.J., Li K. Paf15 expression correlates with rectal cancer prognosis, cell proliferation and radiation response. Oncotarget. 2016;7:38750–38761. doi: 10.18632/oncotarget.9606.
    1. Cebrian A., Gomez Del Pulgar T., Fernandez-Acenero M.J., Borrero-Palacios A., Del Puerto-Nevado L., Martinez-Useros J., Marin-Arango J.P., Carames C., Vega-Bravo R., Rodriguez-Remirez M., et al. Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Pathol. Res. Pract. 2016;212:1133–1137. doi: 10.1016/j.prp.2016.09.012.
    1. Del Puerto-Nevado L., Marin-Arango J.P., Fernandez-Acenero M.J., Arroyo-Manzano D., Martinez-Useros J., Borrero-Palacios A., Rodriguez-Remirez M., Cebrian A., Gomez Del Pulgar T., Cruz-Ramos M., et al. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: A retrospective observational cohort study. BMC Cancer. 2016;16:519. doi: 10.1186/s12885-016-2574-9.
    1. Li X.F., Jiang Z., Gao Y., Li C.X., Shen B.Z. Combination of three-gene immunohistochemical panel and magnetic resonance imaging-detected extramural vascular invasion to assess prognosis in non-advanced rectal cancer patients. World J. Gastroenterol. WJG. 2016;22:8576–8583. doi: 10.3748/wjg.v22.i38.8576.
    1. Zhu K., Zhao Q., Yue J., Shi P., Yan H., Xu X., Wang R. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer. Oncotarget. 2016;7:68328–68338. doi: 10.18632/oncotarget.12008.
    1. Gomez Del Pulgar T., Cebrian A., Fernandez-Acenero M.J., Borrero-Palacios A., Del Puerto-Nevado L., Martinez-Useros J., Marin-Arango J.P., Carames C., Vega-Bravo R., Rodriguez-Remirez M., et al. Focal adhesion kinase: Predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J. Cell. Mol. Med. 2016;20:1729–1736. doi: 10.1111/jcmm.12879.
    1. Ahmed M.A., Selzer E., Dorr W., Jomrich G., Harpain F., Silberhumer G.R., Mullauer L., Holzmann K., Grasl-Kraupp B., Grusch M., et al. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. Oncotarget. 2016 doi: 10.18632/oncotarget.12099.
    1. Voboril R., Rychterova V., Voborilova J., Kubecova M., Fanta J., Dvorak J. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: Prognostic marker for disease progression and survival. Neoplasma. 2016;63:462–470. doi: 10.4149/317_151013N525.
    1. Yu J.I., Lee H., Park H.C., Choi D.H., Choi Y.L., Do I.G., Kim H.C., Lee W.Y., Yun S.H., Cho Y.B., et al. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. Oncotarget. 2016;7:62676–62686. doi: 10.18632/oncotarget.10445.
    1. Peng H., You K., Zhang R., Xi S., Zhang T., Dong J., Cai M., Wang C., Zhang H., Zhou T., et al. Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma. Oncotarget. 2016;7:35233–35240. doi: 10.18632/oncotarget.9125.
    1. Zaanan A., Park J.M., Tougeron D., Huang S., Wu T.T., Foster N.R., Sinicrope F.A. Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int. J. Cancer. 2015;137:1498–1502. doi: 10.1002/ijc.29496.
    1. Croner R.S., Sevim M., Metodiev M.V., Jo P., Ghadimi M., Schellerer V., Brunner M., Geppert C., Rau T., Sturzl M., et al. Identification of Predictive Markers for Response to Neoadjuvant Chemoradiation in Rectal Carcinomas by Proteomic Isotope Coded Protein Label (ICPL) Analysis. Int. J. Mol. Sci. 2016;17:209. doi: 10.3390/ijms17020209.
    1. Chao T.B., Li C.F., Lin C.Y., Tian Y.F., Chang I.W., Sheu M.J., Lee Y.E., Chan T.C., He H.L. Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy. Future Oncol. 2016;12:1457–1467. doi: 10.2217/fon-2016-0071.
    1. Chai C.Y., Zhang Y., Song J., Lin S.C., Sun S., Chang I.W. VNN1 overexpression is associated with poor response to preoperative chemoradiotherapy and adverse prognosis in patients with rectal cancers. Am. J. Transl. Res. 2016;8:4455–4463.
    1. Lee Y.E., He H.L., Shiue Y.L., Lee S.W., Lin L.C., Wu T.F., Chang I.W., Lee H.H., Li C.F. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2015;36:7675–7683. doi: 10.1007/s13277-015-3503-2.
    1. Voboril R., Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: Impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma. 2006;53:518–523.
    1. Redalen K.R., Sitter B., Bathen T.F., Groholt K.K., Hole K.H., Dueland S., Flatmark K., Ree A.H., Seierstad T. High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2016;118:393–398. doi: 10.1016/j.radonc.2015.11.031.
    1. Sharabi A.B., Lim M., DeWeese T.L., Drake C.G. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498–e509. doi: 10.1016/S1470-2045(15)00007-8.
    1. Teng F., Meng X., Kong L., Mu D., Zhu H., Liu S., Zhang J., Yu J. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl. Res. J. Lab. Clin. Med. 2015;166:721–732. doi: 10.1016/j.trsl.2015.06.019.
    1. McCoy M.J., Hemmings C., Miller T.J., Austin S.J., Bulsara M.K., Zeps N., Nowak A.K., Lake R.A., Platell C.F. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br. J. Cancer. 2015;113:1677–1686. doi: 10.1038/bjc.2015.427.
    1. Patel S.P., Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol. Cancer Ther. 2015;14:847–856. doi: 10.1158/1535-7163.MCT-14-0983.
    1. Gibney G.T., Weiner L.M., Atkins M.B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–e551. doi: 10.1016/S1470-2045(16)30406-5.
    1. Hecht M., Buttner-Herold M., Erlenbach-Wunsch K., Haderlein M., Croner R., Grutzmann R., Hartmann A., Fietkau R., Distel L.V. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur. J. Cancer. 2016;65:52–60. doi: 10.1016/j.ejca.2016.06.015.
    1. Saigusa S., Toiyama Y., Tanaka K., Inoue Y., Mori K., Ide S., Imaoka H., Kawamura M., Mohri Y., Kusunoki M. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int. J. Clin. Oncol. 2016;21:946–952. doi: 10.1007/s10147-016-0962-4.
    1. Azizian A., Gruber J., Ghadimi B.M., Gaedcke J. MicroRNA in rectal cancer. World J. Gastrointest. Oncol. 2016;8:416–426. doi: 10.4251/wjgo.v8.i5.416.
    1. Lim S.H., Chua W., Henderson C., Ng W., Shin J.S., Chantrill L., Asghari R., Lee C.S., Spring K.J., de Souza P. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit. Rev. Oncol. Hematol. 2015;96:67–80. doi: 10.1016/j.critrevonc.2015.05.003.
    1. Conde-Muino R., Cuadros M., Zambudio N., Segura-Jimenez I., Cano C., Palma P. Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. BioMed Res. Int. 2015;2015:921435. doi: 10.1155/2015/921435.
    1. Gaedcke J., Grade M., Camps J., Sokilde R., Kaczkowski B., Schetter A.J., Difilippantonio M.J., Harris C.C., Ghadimi B.M., Moller S., et al. The rectal cancer microRNAome—MicroRNA expression in rectal cancer and matched normal mucosa. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012;18:4919–4930. doi: 10.1158/1078-0432.CCR-12-0016.
    1. Carames C., Cristobal I., Moreno V., del Puerto L., Moreno I., Rodriguez M., Marin J.P., Correa A.V., Hernandez R., Zenzola V., et al. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int. J. Colorectal Dis. 2015;30:899–906. doi: 10.1007/s00384-015-2231-9.
    1. Probst C.P., Becerra A.Z., Aquina C.T., Tejani M.A., Hensley B.J., Gonzalez M.G., Noyes K., Monson J.R., Fleming F.J. Watch and Wait?--Elevated Pretreatment CEA Is Associated with Decreased Pathological Complete Response in Rectal Cancer. J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract. 2016;20:43–52. doi: 10.1007/s11605-015-2987-9.
    1. Kim C.H., Lee S.Y., Kim H.R., Kim Y.J. Prognostic Effect of Pretreatment Serum Carcinoembryonic Antigen Level: A Useful Tool for Prediction of Distant Metastasis in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision. Medicine (Baltimore) 2015;94:e1291. doi: 10.1097/MD.0000000000001291.
    1. Song J.H., Kim S.H., Lee J.H., Cho H.M., Kim D.Y., Kim T.H., Kim S.Y., Baek J.Y., Oh J.H., Nam T.K., et al. Significance of histologic tumor grade in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: A multi-institutional retrospective study. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2016;118:387–392. doi: 10.1016/j.radonc.2015.11.028.
    1. Das P., Skibber J.M., Rodriguez-Bigas M.A., Feig B.W., Chang G.J., Wolff R.A., Eng C., Krishnan S., Janjan N.A., Crane C.H. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109:1750–1755. doi: 10.1002/cncr.22625.
    1. Yoon S.M., Kim D.Y., Kim T.H., Jung K.H., Chang H.J., Koom W.S., Lim S.B., Choi H.S., Jeong S.Y., Park J.G. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:1167–1172. doi: 10.1016/j.ijrobp.2007.04.047.
    1. Moreno García V., Cejas P., Blanco Codesido M., Feliu Batlle J., de Castro Carpeño J., Belda-Iniesta C., Barriuso J., Sánchez J.J., Larrauri J., González-Barón M., et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int. J. Colorectal Dis. 2009;24:741–748. doi: 10.1007/s00384-009-0682-6.
    1. Kalady M.F., de Campos-Lobato L.F., Stocchi L., Geisler D.P., Dietz D., Lavery I.C., Fazio V.W. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann. Surg. 2009;250:582–589. doi: 10.1097/SLA.0b013e3181b91e63.
    1. Park J.W., Lim S.B., Kim D.Y., Jung K.H., Hong Y.S., Chang H.J., Choi H.S., Jeong S.Y. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:810–817. doi: 10.1016/j.ijrobp.2008.08.057.
    1. Lee S.D., Park J.W., Park K.S., Lim S.B., Chang H.J., Kim D.Y., Jeong S.Y., Choi H.S., Oh J.H. Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. Int. J. Colorectal Dis. 2009;24:1451–1458. doi: 10.1007/s00384-009-0762-7.
    1. Kang J.H., Kim Y.C., Kim H., Kim Y.W., Hur H., Kim J.S., Min B.S., Lim J.S., Seong J., Keum K.C., et al. Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: The impact of the volume reduction ratio on the prediction of pathologic complete response. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:1018–1025. doi: 10.1016/j.ijrobp.2009.03.066.
    1. Aldulaymi B., Christensen I.J., Sölétormos G., Jess P., Nielsen S.E., Laurberg S., Brünner N., Nielsen H.J. Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer. Anticancer Res. 2010;30:4755–4759.
    1. Yan H., Wang R., Zhu K., Zhao W., Jiang S., Feng R., Xu X., Meng X., Sun H., Zhang H., et al. Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma. Tumori. 2011;97:717–723.
    1. Hur H., Kim N.K., Yun M., Min B.S., Lee K.Y., Keum K.C., Ahn J.B., Kim H. 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. J. Surg. Oncol. 2011;103:17–24. doi: 10.1002/jso.21736.
    1. Moureau-Zabotto L., Farnault B., de Chaisemartin C., Esterni B., Lelong B., Viret F., Giovannini M., Monges G., Delpero J.R., Bories E., et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:483–491. doi: 10.1016/j.ijrobp.2010.02.025.
    1. Wallin U., Rothenberger D., Lowry A., Luepker R., Mellgren A. CEA—A predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis. Colon Rectum. 2013;56:859–868. doi: 10.1097/DCR.0b013e31828e5a72.
    1. Restivo A., Zorcolo L., Cocco I.M., Manunza R., Margiani C., Marongiu L., Casula G. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann. Surg. Oncol. 2013;20:864–871. doi: 10.1245/s10434-012-2669-8.
    1. Lee J.H., Kim S.H., Jang H.S., Chung H.J., Oh S.T., Lee D.S., Kim J.G. Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: A multi-institutional analysis in an Asian population. Int. J. Colorectal Dis. 2013;28:511–517.
    1. Yeo S.G., Kim D.Y., Chang H.J., Park J.W., Oh J.H., Kim B.C., Baek J.Y., Kim S.Y., Kim T.H. Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy. Tumori. 2013;99:93–99.
    1. Yang K.L., Yang S.H., Liang W.Y., Kuo Y.J., Lin J.K., Lin T.C., Chen W.S., Jiang J.K., Wang H.S., Chang S.C., et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat. Oncol. 2013;8:43. doi: 10.1186/1748-717X-8-43.
    1. Wang L., Zhong X.G., Peng Y.F., Li Z.W., Gu J. Prognostic value of pretreatment level of carcinoembryonic antigen on tumour downstaging and early occurring metastasis in locally advanced rectal cancer following neoadjuvant radiotherapy (30 Gy in 10 fractions) Colorectal Dis. Off. J. Assoc. Coloproctol. Great Br. Irel. 2014;16:33–39. doi: 10.1111/codi.12354.
    1. Kleiman A., Al-Khamis A., Farsi A., Kezouh A., Vuong T., Gordon P.H., Vasilevsky C.A., Morin N., Faria J., Ghitulescu G., et al. Normalization of CEA Levels Post-Neoadjuvant Therapy is a Strong Predictor of Pathologic Complete Response in Rectal Cancer. J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract. 2015;19:1106–1112. doi: 10.1007/s11605-015-2814-3.
    1. Zhang L.-N., OuYang P.-Y., Xiao W.-W., Yu X., You K.-Y., Zeng Z.-F., Xu R.-H., Gao Y.-H. Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Medicine. 2015;94:e1793. doi: 10.1097/MD.0000000000001793.
    1. Lee J.H., Hyun J.H., Kim D.Y., Yoo B.C., Park J.W., Kim S.Y., Chang H.J., Kim B.C., Kim T.H., Oh J.H., et al. The Role of Fibrinogen as a Predictor in Preoperative Chemoradiation for Rectal Cancer. Ann. Surg. Oncol. 2015;22:209–215. doi: 10.1245/s10434-014-3962-5.
    1. Hektoen H.H., Flatmark K., Andersson Y., Dueland S., Redalen K.R., Ree A.H. Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer. BMC Cancer. 2015;15:543. doi: 10.1186/s12885-015-1557-6.
    1. Crotti S., Enzo M.V., Bedin C., Pucciarelli S., Maretto I., del Bianco P., Traldi P., Tasciotti E., Ferrari M., Rizzolio F., et al. Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. J. Cell. Physiol. 2015;230:1822–1828. doi: 10.1002/jcp.24894.
    1. Kim K., Yeo S.G., Yoo B.C. Identification of hypoxanthine and phosphoenolpyruvic Acid as serum markers of chemoradiotherapy response in locally advanced rectal cancer. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2015;47:78–89. doi: 10.4143/crt.2013.127.
    1. D’Angelo E., Fassan M., Maretto I., Pucciarelli S., Zanon C., Digito M., Rugge M., Nitti D., Agostini M. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. Oncotarget. 2016;7:28647–28657. doi: 10.18632/oncotarget.8725.
    1. Yu J., Li N., Wang X., Ren H., Wang W., Wang S., Song Y., Liu Y., Li Y., Zhou X., et al. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget. 2016 doi: 10.18632/oncotarget.11649.
    1. Alix-Panabieres C., Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer. 2014;14:623–631. doi: 10.1038/nrc3820.
    1. Sun W., Huang T., Li G., Shen W., Zhu J., Jin Q., Zhao J., Jia C., Zhang Z. The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. Future Oncol. 2013;9:1489–1500. doi: 10.2217/fon.13.91.
    1. Sun W., Jia C., Huang T., Sheng W., Li G., Zhang H., Jing F., Jin Q., Zhao J., Li G., Zhang Z. High-performance size-based microdevice for the detection of circulating tumor cells from peripheral blood in rectal cancer patients. PLoS ONE. 2013;8:e75865. doi: 10.1371/journal.pone.0075865.
    1. Sun W., Li G., Wan J., Zhu J., Shen W., Zhang Z. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;7:69507–69517. doi: 10.18632/oncotarget.10875.
    1. Magni E., Botteri E., Ravenda P.S., Cassatella M.C., Bertani E., Chiappa A., Luca F., Zorzino L., Bianchi P.P., Adamoli L., et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int. J. Colorectal. Dis. 2014;29:1053–1059. doi: 10.1007/s00384-014-1958-z.
    1. Hinz S., Röder C., Tepel J., Hendricks A., Schafmayer C., Becker T., Kalthoff H. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer. 2015;15:953. doi: 10.1186/s12885-015-1989-z.
    1. Nesteruk D., Rutkowski A., Fabisiewicz S., Pawlak J., Siedlecki J.A., Fabisiewicz A. Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: Prospectively collected material data. BioMed Res. Int. 2014;2014:712827. doi: 10.1155/2014/712827.
    1. Sun W., Sun Y., Zhu M., Wang Z., Zhang H., Xin Y., Jiang G., Guo X., Zhang Z., Liu Y. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol. Rep. 2014;31:1466–1472.
    1. Tada N. Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients. Oncol. Rep. 2013;31:163–471. doi: 10.3892/or.2013.2857.
    1. Zezulova M., Bartouskova M., Hlidkova E., Juranova J., Cervinkova B., Kasalova E., Adam T., Krcmova L.K., Solichova D., Cwiertka K., et al. Prognostic Significance of Serum and Urinary Neopterin Concentrations in Patients with Rectal Carcinoma Treated with Chemoradiation. Anticancer Res. 2016;36:287–292.
    1. Caputo D., Caricato M., Coppola A., la Vaccara V., Fiore M., Coppola R. Neutrophil to Lymphocyte Ratio (NLR) and Derived Neutrophil to Lymphocyte Ratio (d-NLR) Predict Non-Responders and Postoperative Complications in Patients Undergoing Radical Surgery After Neo-Adjuvant Radio-Chemotherapy for Rectal Adenocarcinoma. Cancer Investig. 2016;34:440–451. doi: 10.1080/07357907.2016.1229332.
    1. Dong Y.W., Shi Y.Q., He L.W., Su P.Z. Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: A meta-analysis. Oncotargets Ther. 2016;9:3127–3134.
    1. Dreyer S.B., Powell A.G.M.T., McSorley S.T., Waterston A., Going J.J., Edwards J., McMillan D.C., Horgan P.G. The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer. Ann. Surg. Oncol. 2016 doi: 10.1245/s10434-016-5684-3.
    1. Maring E.D., Tawadros P.S., Steer C.J., Lee J.T. Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer. Anticancer Res. 2015;35:3761–3766.
    1. Kim J.C., Ha Y.J., Roh S.A., Cho D.H., Choi E.Y., Kim T.W., Kim J.H., Kang T.W., Kim S.Y., Kim Y.S. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2013;86:350–357. doi: 10.1016/j.ijrobp.2012.12.018.
    1. Nikas J.B., Lee J.T., Maring E.D., Washechek-Aletto J., Felmlee-Devine D., Johnson R.A., Smyrk T.C., Tawadros P.S., Boardman L.A., Steer C.J. A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. Am. J. Cancer Res. 2015;5:3231–3240.
    1. Cecchin E., Agostini M., Pucciarelli S., de Paoli A., Canzonieri V., Sigon R., de Mattia E., Friso M.L., Biason P., Visentin M., et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharm. J. 2010;11:214–226. doi: 10.1038/tpj.2010.25.
    1. Nelson B., Carter J.V., Eichenberger M.R., Netz U., Galandiuk S. Genetic polymorphisms in 5-Fluorouracil–related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer. Surgery. 2016;160:1326–1332. doi: 10.1016/j.surg.2016.05.017.
    1. Qin Y.Z., Tang F., Chen J.S., Lin Y., Lai H. DNA repair gene XPG C46T polymorphism predicts response to platinum-based neoadjuvant chemoradiotherapy and prognosis in clinical stage II/III rectal cancer patients. Int. J. Clin. Exp. Pathol. 2016;9:6326–6333.
    1. Dreussi E., Cecchin E., Polesel J., Canzonieri V., Agostini M., Boso C., Belluco C., Buonadonna A., Lonardi S., Bergamo F., et al. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. Int. J. Mol. Sci. 2016;17:1482. doi: 10.3390/ijms17091482.
    1. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454:56–61. doi: 10.1038/nature07086.
    1. Dreussi E., Pucciarelli S., de Paoli A., Polesel J., Canzonieri V., Agostini M., Friso M.L., Belluco C., Buonadonna A., Lonardi S., et al. Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Oncotarget. 2016;7:19781–19793. doi: 10.18632/oncotarget.7757.
    1. Vymetalkova V., Pardini B., Rosa F., Jiraskova K., di Gaetano C., Bendova P., Levy M., Veskrnova V., Buchler T., Vodickova L., et al. Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients. Carcinogenesis. 2016;38:28–39. doi: 10.1093/carcin/bgw114.
    1. Naccarati A., Rosa F., Vymetalkova V., Barone E., Jiraskova K., di Gaetano C., Novotny J., Levy M., Vodickova L., Gemignani F., et al. Double-strand break repair and colorectal cancer: Gene variants within 3′ UTRs and microRNAs binding as modulators of cancer risk and clinical outcome. Oncotarget. 2016;7:23156–23169. doi: 10.18632/oncotarget.6804.
    1. Pardini B., Rosa F., Barone E., di Gaetano C., Slyskova J., Novotny J., Levy M., Garritano S., Vodickova L., Buchler T., et al. Variation within 3’-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013;19:6044–6056. doi: 10.1158/1078-0432.CCR-13-0314.
    1. Guinney J., Dienstmann R., Wang X., de Reynies A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P., et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015;21:1350–1356. doi: 10.1038/nm.3967.
    1. Sottoriva A., Kang H., Ma Z., Graham T.A., Salomon M.P., Zhao J., Marjoram P., Siegmund K., Press M.F., Shibata D., et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 2015;47:209–216. doi: 10.1038/ng.3214.
    1. Kim T.M., Jung S.H., An C.H., Lee S.H., Baek I.P., Kim M.S., Park S.W., Rhee J.K., Lee S.H., Chung Y.J. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015;21:4461–4472. doi: 10.1158/1078-0432.CCR-14-2413.
    1. Hong T.S., Clark J.W., Haigis K.M. Cancers of the colon and rectum: Identical or fraternal twins? Cancer Discov. 2012;2:117–121. doi: 10.1158/-11-0315.
    1. Tamas K., Walenkamp A.M., de Vries E.G., van Vugt M.A., Beets-Tan R.G., van Etten B., de Groot D.J., Hospers G.A. Rectal and colon cancer: Not just a different anatomic site. Cancer Treat. Rev. 2015;41:671–679. doi: 10.1016/j.ctrv.2015.06.007.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera